--> --> -->

Blogs

19
Jan 2024

VeriPac Series for Class III Medical Device Package Inspection

VeriPac Series for Class III Medical Device Package Inspection

Class III medical devices in the United States are subject to stringent regulation by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act. These devices, characterized by their high-risk nature, include those vital to sustaining human life or preventing health impairment, as well as those posing potential, unreasonable risks of illness or injury.

Examples of Class III devices encompass implantable pacemakers, specific prosthetic devices, and innovative technologies such as certain in vitro diagnostic devices. Classification is determined by factors like intended use, indications, and associated risks. Due to their complexity and critical roles in medical procedures, Class III devices undergo a rigorous pre-market approval (PMA) process.

Manufacturers must furnish extensive scientific and clinical evidence to demonstrate a device's safety and efficacy before it can be marketed. This robust regulatory framework ensures that Class III medical devices meet the highest standards for safety and performance, safeguarding patient health.

Packaging for these devices plays a critical role in maintaining the integrity of the product, ensuring it reaches the end user in a safe and effective condition. The packaging of Class III medical devices faces unique challenges due to the stringent regulatory requirements and the critical nature of the enclosed products. Ensuring the integrity of the packaging is essential to prevent contamination, maintain sterility, and safeguard the efficacy of the medical devices.

How to Ensure Container Closure Integrity of Class III Medical Device Packaging

Container Closure Integrity (CCI) is a vital aspect of ensuring the reliability of Class III medical device packaging . CCI testing involves assessing the seals and closures to confirm they effectively prevent the ingress of contaminants and maintain the sterility of the device. This testing is crucial to meeting regulatory standards and ensuring patient safety.

PTI’s VeriPac series are non-destructive, non-invasive inspection systems for leak detection and package integrity testing. These systems reduce waste and provide operators with a clear understanding of package quality. The VeriPac test system produces real time results from precise quantitative measurements that identify packaging defects before critical process issues get out of control. Tests can be performed in any sequence and even repeatedly on a single sample. Good packages can be returned undamaged to the packaging line. Testing is more reliable, sensitive and efficient than destructive methods. VeriPac series utilizes the ASTM approved patented Vacuum Decay leak test method F2338, recognized by the FDA as a consensus standard for package integrity testing.

Technology Overview

PTI’s VeriPac leak testers connect to a test chamber that is specially designed to contain the package to be tested. The package is placed inside the test chamber to which vacuum is applied. The absolute transducer technology is used to monitor the test chamber for both, the level of vacuum as well as the change in vacuum over a predetermined test time. The changes in absolute and differential vacuum indicate the presence of leaks and defects within the package. The test cycle takes only a few seconds, results are non-subjective, and testing is non-destructive to both product and package. The sensitivity of a test is a function of the sensitivity of the transducer, the package design, the package test fixture and critical test parameters of time and pressure. Test systems can be designed for manual or fully automated operation. This inspection method is suitable for laboratory offline testing, QA/QC statistical process control, automated batch or 100% inline testing.

Benefits of VeriPac series

  • Non-destructive, non-subjective, no sample preparation
  • Deterministic, quantitative test method
  • Defect detection down to single digit microns.
  • High level of sensitivity, repeatability and accuracy
  • Short cycle time provides operator with PASS/FAIL result
  • Small footprint and modular portable design
  • ASTM test method and FDA standard
  • Referenced in USP 1207 guidance
Readmore...
VeriPac Series, Class III Medical Device Package Inspection, cci, container closure integrity, ccit, cci testing
652

Popular Blogs

Tags

CCIT for Pharmaceutical Package Integrity

Jul 23, 2021   |   2733

Container Closure Integrity Testing of pharmaceutical packaging ensures that the products remain intact throughout its shelf life or until it reaches the end user.

Why is Seal Integrity Testing of Medical Device Packaging Important

Jul 29, 2021   |   2471

For sterile medical devices, seal integrity testing ensures product efficacy, shelf-life stability, and microbial sterility. Airborne Ultrasound technology is a non-destructive Container Closure Integrity test method, capable of examining seal quality for defects.

A Guide to MicroCurrent HVLD Technology

Aug 05, 2021   |   2375

In the case of parenteral drug product containers, HVLD technology is ideal for CCI testing in cases where packaging is less conductive than the liquid within.

Pre-filled Syringes Leak Detection with Vacuum Decay Vs MicroCurrent HVLD Test Methods

Nov 23, 2021   |   2063

Container Closure Integrity (CCI) can be challenged using various test methods, not all of which are equally capable of detecting leaks in the package.

Evaluating Package Integrity Solutions for Vials

Nov 30, 2021   |   2062

CCI testing is a critical component of quality assurance for vials. The defects which cause a sterile vial to leak are not necessarily defects that will be detected.
Popup